[CME-Laboratory 61: New European Consensus Recommendations on Dyslipidemia]

Area of Science:

• Cardiology
• Clinical Chemistry
• Atherosclerosis Research

Background:

• Lipid status is crucial for estimating atherosclerotic cardiovascular disease (ASCVD) risk.
• Low-density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies.
• Non-HDL cholesterol and apolipoprotein B serve as secondary targets.

Purpose of the Study:

• To summarize the new European consensus recommendations on dyslipidemia management.
• To highlight changes in treatment targets for various ASCVD risk groups.
• To address the role of emerging lipid risk factors and diagnostic quality.

Main Methods:

• Review of new European Cardiology and Atherosclerosis Societies' consensus guidelines.
• Analysis of lipid risk factors including LDL-C, non-HDL-C, apolipoprotein B, triglycerides, HDL-C, and lipoprotein (a).
• Assessment of current laboratory diagnostic quality and its limitations.

Main Results:

• European guidelines have lowered treatment targets for all ASCVD risk groups.
• Triglycerides and HDL cholesterol are recommended for risk assessment but not as therapeutic goals.
• Lipoprotein (a) is a significant, genetically determined ASCVD risk factor, partly resistant to statins.

Conclusions:

• The quality of laboratory diagnostics for lipid risk factors requires enhancement.
• Improved diagnostics are essential given the introduction of new, expensive lipid-modifying therapies.
• Adherence to updated European guidelines is vital for effective ASCVD risk management.